Literature DB >> 32851370

Kinesiophobia Levels in Fibromyalgia Syndrome and the Relationship Between Pain, Disease Activity, Depression.

Burhan Fatih KoÇyİĞİt1, Mazlum Serdar Akaltun2.   

Abstract

OBJECTIVES: This study aims to compare kinesiophobia levels between patients with fibromyalgia syndrome (FMS) and healthy volunteers and to investigate the factors associated with kinesiophobia in FMS. PATIENTS AND METHODS: This case-control study included 88 female patients with FMS (mean age 41.61 years; range 21 to 61 years) and 67 female healthy volunteers (mean age 41.34 years; range 19 to 59 years). The participants' age, body mass index (BMI), and educational status were recorded. Patients were evaluated using a visual analog scale for pain, the Fibromyalgia Impact Questionnaire (FIQ) for disease activity, the Hamilton Depression Scale (HAM-D) for depression level, and the Tampa Scale for Kinesiophobia (TSK) for kinesiophobia. Additionally, the patients' serum 25-hydroxyvitamin D levels were measured.
RESULTS: No significant differences were found between the patient and control groups in terms of age, BMI, and educational status (p>0.05). The mean TSK scores were 42.0±7.6 in the patient group and 37.2±8.8 in the control group. TSK score was significantly higher in the patient group (p<0.001). BMI levels, FIQ scores, and vitamin D concentrations were significantly associated with TSK scores according to the linear regression analysis (p<0.05). However, age, symptom duration, and HAM-D scores were not found to be associated with TSK scores (p>0.05).
CONCLUSION: Kinesiophobia scores were significantly higher in patients with FMS. Physicians should focus on kinesiophobia when evaluating patients with FMS and inform patients about the importance and treatment strategies of kinesiophobia.
Copyright © 2020, Turkish League Against Rheumatism.

Entities:  

Keywords:  Fear of movement; fibromyalgia; kinesiophobia; vitamin D

Year:  2020        PMID: 32851370      PMCID: PMC7406166          DOI: 10.46497/ArchRheumatol.2020.7432

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.007


  22 in total

1.  Prevalence of fibromyalgia and chronic widespread pain.

Authors:  L Lindell; S Bergman; I F Petersson; L T Jacobsson; P Herrström
Journal:  Scand J Prim Health Care       Date:  2000-09       Impact factor: 2.581

2.  Fear of movement: factor structure of the tampa scale of kinesiophobia in patients with fibromyalgia syndrome.

Authors:  Tasha Burwinkle; James P Robinson; Dennis C Turk
Journal:  J Pain       Date:  2005-06       Impact factor: 5.820

Review 3.  The role of vitamin D in pathophysiology and treatment of fibromyalgia.

Authors:  Carlos A S Jesus; David Feder; Mario F P Peres
Journal:  Curr Pain Headache Rep       Date:  2013-08

Review 4.  The fear-avoidance model of musculoskeletal pain: current state of scientific evidence.

Authors:  Maaike Leeuw; Mariëlle E J B Goossens; Steven J Linton; Geert Crombez; Katja Boersma; Johan W S Vlaeyen
Journal:  J Behav Med       Date:  2006-12-20

Review 5.  Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art.

Authors:  Johan W S Vlaeyen; Steven J Linton
Journal:  Pain       Date:  2000-04       Impact factor: 6.961

6.  The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.

Authors:  Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield; Muhammad B Yunus
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

7.  Kinesiophobia and maladaptive coping strategies prevent improvements in pain catastrophizing following pain neuroscience education in fibromyalgia/chronic fatigue syndrome: An explorative study.

Authors:  Anneleen Malfliet; Jessica Van Oosterwijck; Mira Meeus; Barbara Cagnie; Lieven Danneels; Mieke Dolphens; Ronald Buyl; Jo Nijs
Journal:  Physiother Theory Pract       Date:  2017-06-12       Impact factor: 2.279

8.  The prevalence and characteristics of fibromyalgia in the general population.

Authors:  F Wolfe; K Ross; J Anderson; I J Russell; L Hebert
Journal:  Arthritis Rheum       Date:  1995-01

9.  Relationship between kinesiophobia and pain, quality of life, functional status, disease activity, mobility, and depression in patients with ankylosing spondylitis

Authors:  Deran Oskay; Zeynep Tuna; İrem Düzgün; Bülent Elbasan; Yavuz Yakut; Abdurrahman Tufan
Journal:  Turk J Med Sci       Date:  2017-11-13       Impact factor: 0.973

Review 10.  Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition.

Authors:  Lars Arendt Nielsen; Karl G Henriksson
Journal:  Best Pract Res Clin Rheumatol       Date:  2007-06       Impact factor: 4.098

View more
  3 in total

1.  Kinesiophobia Levels in Patients with Parkinson's Disease: A Case-Control Investigation.

Authors:  Ana María Jiménez-Cebrián; Ricardo Becerro-de-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Carmen de Labra; César Calvo-Lobo; Patricia Palomo-López; Eva María Martínez-Jiménez; Emmanuel Navarro-Flores
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

2.  Relationship between Kinesiophobia and Mobility, Impact of the Disease, and Fear of Falling in Women with and without Fibromyalgia: A Cross-Sectional Study.

Authors:  Juan Luis Leon-Llamas; Alvaro Murillo-Garcia; Santos Villafaina; Francisco Javier Domínguez-Muñoz; Jesús Morenas; Narcis Gusi
Journal:  Int J Environ Res Public Health       Date:  2022-07-06       Impact factor: 4.614

3.  Catastrophizing, Kinesiophobia, and Acceptance as Mediators of the Relationship Between Perceived Pain Severity, Self-Reported and Performance-Based Physical Function in Women with Fibromyalgia and Obesity.

Authors:  Giorgia Varallo; Carlos Suso-Ribera; Ada Ghiggia; Marco Veneruso; Roberto Cattivelli; Anna Guerrini Usubini; Christian Franceschini; Alessandro Musetti; Giuseppe Plazzi; Jacopo Maria Fontana; Paolo Capodaglio; Gianluca Castelnuovo
Journal:  J Pain Res       Date:  2022-09-26       Impact factor: 2.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.